These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 17965003)

  • 1. [Therapeutic response evaluation by nuclear functional imaging].
    Moretti JL; Hindie E; Vercellino L
    Bull Cancer; 2007; 94(7 Suppl):F241-4. PubMed ID: 17965003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Positron emission tomography and evaluation of response to targeted therapies].
    Gauthier H
    Bull Cancer; 2009 Nov; 96(11):1087-97. PubMed ID: 19875353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Where do we draw the line? Contouring tumors on positron emission tomography/computed tomography.
    Macmanus MP; Hicks RJ
    Int J Radiat Oncol Biol Phys; 2008 May; 71(1):2-4. PubMed ID: 18406881
    [No Abstract]   [Full Text] [Related]  

  • 4. Heavy PETting: reducing radiation exposure from intradepartment positron emission tomography scans.
    Bornstein S; Young K; Tanyi J; Holland J
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):545. PubMed ID: 24368063
    [No Abstract]   [Full Text] [Related]  

  • 5. Contouring carcinomas by FDG-PET: is the role of tumor biology underestimated? In regard to MacManus et al. (Int J Radiat Oncol Biol Phys 2008;71:2-4).
    Farace P; Galiè M; Nanni C; Spinelli A; Fanti S
    Int J Radiat Oncol Biol Phys; 2008 Sep; 72(1):303-4; author reply 304. PubMed ID: 18722288
    [No Abstract]   [Full Text] [Related]  

  • 6. [Evaluation of therapies in oncology by positron emission tomography: towards therapeutical personalization].
    Bonardel G; Vedrine L; Aupee O; Gontier E; Le Garlantezec P; Soret M; Foehrenbach H
    Bull Cancer; 2009 Feb; 96(2):213-26. PubMed ID: 19258228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of clinical practice utility of positron emission tomography with 18F-fluorodeoxyglucose in assessing tumour response to therapy.
    d'Amico A
    Radiol Med; 2015 Apr; 120(4):345-51. PubMed ID: 25155349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining co-related parameters between 'metabolic' flare and 'clinical', 'biochemical', and 'osteoblastic' flare and establishing guidelines for assessing response to treatment in cancer.
    Basu S; Alavi A
    Eur J Nucl Med Mol Imaging; 2007 Apr; 34(4):441-3. PubMed ID: 17072613
    [No Abstract]   [Full Text] [Related]  

  • 9. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.
    Larson SM; Schwartz LH
    J Nucl Med; 2006 Jun; 47(6):901-3. PubMed ID: 16741296
    [No Abstract]   [Full Text] [Related]  

  • 11. Primer on imaging technologies for cancer.
    Schnall M; Rosen M
    J Clin Oncol; 2006 Jul; 24(20):3225-33. PubMed ID: 16829646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Use of PET for evaluation of treatment response in oncology].
    Bourguet P
    Cancer Radiother; 2006 Nov; 10(6-7):334-7. PubMed ID: 16950641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Restaging: should we percist without pattern recognition?
    Hofman MS; Hicks RJ
    J Nucl Med; 2010 Dec; 51(12):1830-2. PubMed ID: 21078792
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical molecular imaging with positron emission tomography.
    Saleem A; Charnley N; Price P
    Eur J Cancer; 2006 Aug; 42(12):1720-7. PubMed ID: 16797972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG imaging: pitfalls and artifacts.
    Abouzied MM; Crawford ES; Nabi HA
    J Nucl Med Technol; 2005 Sep; 33(3):145-55; quiz 162-3. PubMed ID: 16145222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of the therapeutic response: role of isotopic imaging].
    Cachin F; Kelly A; Maublant J
    Bull Cancer; 2006 Dec; 93(12):1191-9. PubMed ID: 17182375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiologists urge FDA to accept PET-based tumor response criteria in clinical trials.
    Brower V
    J Natl Cancer Inst; 2011 Apr; 103(8):622-4. PubMed ID: 21474833
    [No Abstract]   [Full Text] [Related]  

  • 18. Normal variants in [18F]-fluorodeoxyglucose PET imaging.
    El-Haddad G; Alavi A; Mavi A; Bural G; Zhuang H
    Radiol Clin North Am; 2004 Nov; 42(6):1063-81, viii. PubMed ID: 15488558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 18F-fluorodeoxyglucose uptake and apparent diffusion coefficient in lung schwannoma.
    Ushiyama T; Katsuda E; Tanaka M; Numanami H; Takahashi E; Baba K; Yamaguchi E; Yokoi T; Haniuda M; Kubo A
    Clin Imaging; 2012; 36(1):65-7. PubMed ID: 22226446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unusual loss of FDG uptake in recurrent GIST.
    Dunzinger A; Decker J; Kieberger A; Weis S; Pichler R
    Nuklearmedizin; 2014 Aug; 53(4):N35-7. PubMed ID: 25100559
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.